Article Text

PDF

Acute treatment of myasthenia gravis with intranasal neostigmine: clinical and electromyographic evaluation.
  1. R Ricciardi,
  2. B Rossi,
  3. M Nicora,
  4. A Sghirlanzoni,
  5. A Muratorio
  1. Institute of Neurological Clinic, University of Pisa, Italy.

    Abstract

    The effectiveness of intranasal neostigmine (9.3-13.8 mg) was tested in 20 subjects with myasthenia gravis, classified as Osserman grades 2A and 2B. In all cases the drug produced significant clinical and electromyographic improvement. No side effects were reported during the treatment.

    Statistics from Altmetric.com

    Request permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.